Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASH 2023 AML Highlights
Featuring presentations & discussions on selected AML abstracts from the 65th ASH Annual Meeting

24 Jan 2024 | 8am-12:30pm CST / 2-6:30pm GMT / 3-7:30pm CET

Please note that this meeting has passed – the recordings will be available on VJHemOnc soon   

Chair: Naval Daver | Moderators: Charles Craddock, Courtney DiNardo, Amir Fathi, Marina Konopleva, Mark Levis,
Sanam Loghavi, Alexander Perl, Gail Roboz, Elizabeth Shpall, Eytan Stein, Marion Subklewe

*Please note: This webinar is for HCPs and allied health professionals only.
Your application to attend will be reviewed and confirmed by VJHemOnc.

Draft Agenda

8:00-8:50am CST

Session 1: Novel Therapies                 
  1. Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Ven in Phase 1/2 Trial of Patients R/R AML; (162) Naval Daver
  2. A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with R/R Acute Leukemia Harboring KMT2A or NPM1 Alterations; (57) Elias Jabbour
  3. Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Ven in AML (SAVE); (58) Ghayas Issa 
  4. Revumenib Monotherapy in R/R KMT2Ar Acute Leukemias: Efficacy and Safety from Augment-101 Phase 1/2 Study; (2907) Ibrahim Aldoss
  5. Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients: Results from the Harmony Platform; (62) Alberto Hernández Sánchez 

Live Q&A

8:50-09:30am

Session 2: FLT3-Mutated Disease
  1. Phase I/II Study of Quizartinib, Ven, and Decitabine Triple Combination in FLT3-ITD Mutated AML; (158) Musa Yilmaz
  2. Quantum-First Trial: FLT3-ITD–Specific MRD Clearance Assessed through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML (pts); (832) Alexander Perl
  3. The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 AML: Analysis of Pethema Quiwi;  (974) Adrián Mosquera Orgueira
  4. Post-Hoc Analysis of MRD from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated; (973) Mark Levis

Live Q&A

9:30-10:00am

Session 3: IDH-Mutated Disease
  1. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Ven Plus Ivosidenib or Enasidenib: 2023 Update; (968) Himachandana Atluri
  2. Comparison of AML Regimens: HMAs Combined with Ivosidenib or Ven in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study; (971) Douglas Smith

Live Q&A

10:00-10:35am

Session 4: NPM1-Mutated Disease
  1. Ven Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild Type Populations; (423) Chong Chyn Chua
  2. Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1-Mutated AML Patients – Results from a Large Cohort of Intensively Treated Patients; (721) Christoph Röllig
  3. Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1-Mutated Myeloid Malignancies; (818) Curtis Lachowiez

Live Q&A

10:35-11:10am

Session 5: Transplantation
  1. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with AlloSCT: Evidence from a Large Real-World Italian Study; (731) Fabio Guolo
  2. Relapse Incidence Post Unrelated AlloSCT with PTCy Vs. Conventional Anti-GvHD Prophylaxis in pts with AML: A Study on Behalf of the Acute Leukemia Working Party of the EBMT; (237) Arnon Nagler
  3. The Benefit of Allo Transplant in 1st Complete Remission in NPM1-Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction – an Analysis of the UK NCRI AML17 and AML19 Studies; (425) Jad Othman

Live Q&A

11:10-11:50am

Session 6: Chemotherapy Combinations
  1. Ven Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for R/R AML: Updated Results of the Phase-I/II SAL Relax Trial; (160) Christoph Röllig
  2. MRD-Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial; (830) Nigel Russel
  3. A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Ven for Older and/or Unfit Patients with AML; (833) Alexandre Bazinet
  4. Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia; (2906) Naval Daver

Live Q&A

11:50am-12:25pm

Session 7: Stratification
  1. Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in AML: Influence of Intensity and Type of Treatment; (723) Alex Bataller
  2. Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Aza, Ven, and Magrolimab Reveals Mechanisms of Response and Resistance; (64) Hussein Abbas
  3. Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients; (955) Xin Wang

Live Q&A

12:30pm CST | End of webinar

The Post-ASH 2023 AML Highlights has been supported by:

The content of VJHemOnc is intended for healthcare professionals